Abstract
The therapeutic potential of cannabis has been harnessed for thousands of years yet the United States Food and Drug Administration (FDA) has still not approved cannabis as a safe or effective drug. The FDA has, however, approved the manufacturing of pharmaceutical drugs, which contain a “synthetic version of a substance that is present in the marijuana” and other compounds that mimic its action. A search of the US National Library of Medicine and National Institute of Health for keywords “CBD” and “Periodontitis” together yields only 2 publications. Although the current State and Federal regulations on the use of cannabis for research and medicinal purposes seem to contradict one another, there is much room for optimism as the number of States allowing its use increases. This manuscript highlights the recent advances made in cannabinoid research as it pertains to oral health and gingival inflammatory disease. With a brief overview of the endocannabinoid system and its network of receptors and ligands, such as CBD, this manuscript provides the reader with the foundational knowledge necessary to answer common patient questions in a clinical setting.
Recommended Citation
Ohanian, Nick Narek
(2020)
"COMMENTARY: Phytocannabinoids as therapeutic agents to combat chronic gingival disease.,"
Pacific Journal of Health: Vol. 3:
Iss.
1, Article 1.
DOI: https://doi.org/10.56031/2576-215X.1007
Available at:
https://scholarlycommons.pacific.edu/pjh/vol3/iss1/1
Included in
Dental Hygiene Commons, Other Dentistry Commons, Periodontics and Periodontology Commons, Pharmaceutics and Drug Design Commons
